IL6 and COVID-19: However, the same study showed that plasma IL-6 levels present a more specific biomarker of neurological deficits after COVID-19 since elevation of IL-6 was observed specifically in neuro-long COVID-19 as compared to long COVID-19 without neurological symptoms (Sun et al., 2021).